Liver Stiffness (LSM) in Dynamic Monitoring: Risk Stratification of Portal Hypertension and HCC
LSM and Risk of Hepatocellular Carcinoma (HCC)
Liver stiffness is a validated predictor of HCC risk: in a prospective cohort of 866 patients with chronic hepatitis C (Masuzaki et al., Hepatology 2009), the cumulative incidence of HCC increased with baseline LSM, and the relative risk (adjusted for age, gender, and cirrhosis) reached 16.7; 20.0; 25.6 and 45.5 for LSM ranges of 10–15; 15–20; 20–25 and > 25 kPa respectively (reference — LSM ≤ 10 kPa).
| Baseline LSM (TE) | Relative Risk of HCC* | 3-year Incidence of HCC |
|---|---|---|
| ≤ 10 kPa | 1 (reference) | ≈ 0.4% |
| 10–15 kPa | 16.7 | — |
| 15–20 kPa | 20.0 | — |
| 20–25 kPa | 25.6 | — |
| > 25 kPa | 45.5 | ≈ 38.5% |
*Masuzaki et al., 2009. In MASLD, HCC screening is advisable at LSM ≥ 10 kPa (especially with diabetes). Absolute thresholds depend on etiology and do not replace comprehensive stratification, but dynamic LSM increase is a significant signal of elevated cancer risk.
LSM Thresholds for Assessing Portal Hypertension
According to guidelines (Ferraioli et al., 2018):
- Recommendation 10: LSM by TE >20 kPa can be used to identify patients with likely clinically significant portal hypertension (HVPG >10 mmHg) — LoE 2b, GoR B.
- Recommendation 11: LSM by TE <20–25 kPa combined with platelet count >110–150 ×10⁹/mL is useful for excluding varices requiring treatment — LoE 2b, GoR B.
Important: changes in LSM do not correlate with changes in HVPG in patients on non-selective beta-blocker therapy (Reiberger et al., 2012).
Dynamic Monitoring (Follow-up)
Annual LSM measurement for monitoring patients with portal hypertension has been proposed (de Franchis, Baveno 2015), but not yet validated. This limits the interpretation of LSM dynamics as an independent prognostic criterion.
Approximate Fibrosis Thresholds (point SWE / ElastPQ)
| Stage | Threshold (EFSUMB, ElastPQ) |
|---|---|
| F0–F1 | < 7.0 kPa |
| F ≥ 2 | ≥ 7.0 kPa |
| F ≥ 3 | ≥ 9.0–9.5 kPa |
| F4 (cirrhosis) | ≥ 12.0–13.0 kPa |
Exact thresholds vary by etiology: higher in ALD and cholestasis, lower in NAFLD.
Conditions for Accurate Measurement
The reliability of LSM is influenced by: food intake (recommended fasting ≥4 hours per point SWE / ElastPQ protocol), presence of inflammation (ALT control), congestion. Study quality is assessed by the criterion IQR/Med ≤ 30% (median of 10 measurements); intercostal access, right lobe (segments V–VIII), area of interest 1–3 cm from the capsule without including the capsule.
Additional Tool: Splenomegaly and LSSM
The cited literature discusses a strategy for screening varices by measuring liver and spleen stiffness (LSSM) in patients with cirrhosis (Wong GLH et al., Liver Int 2018; Hepatology 2019) — as an additional approach to risk stratification of variceal bleeding.
Frequently asked questions
Are there LSM thresholds for HCC risk?
Yes: according to Masuzaki et al. (2009), the relative risk of HCC increases with LSM — 16.7; 20.0; 25.6; 45.5 at 10–15; 15–20; 20–25; >25 kPa compared to ≤10 kPa; 3-year incidence of HCC ranges from ≈0.4% to ≈38.5%. In MASLD, screening is justified from LSM ≥10 kPa (especially with diabetes).
What LSM threshold indicates clinically significant portal hypertension?
LSM by TE >20 kPa (Ferraioli et al., 2018, Recommendation 10, LoE 2b, GoR B) identifies likely clinically significant portal hypertension (HVPG >10 mmHg).
How to exclude varices requiring treatment?
LSM by TE <20–25 kPa combined with platelets >110–150 ×10⁹/L (Recommendation 11, LoE 2b, GoR B).
Can LSM dynamics be monitored annually?
Annual LSM measurement in portal hypertension has been proposed (de Franchis, Baveno 2015), but not yet validated; changes in LSM do not correlate with changes in HVPG on beta-blocker therapy.
What conditions are necessary for accurate measurement?
Fasting ≥4 hours, control of inflammation (ALT), absence of congestion; quality criterion IQR/Med ≤30% with a median of 10 measurements, intercostal access, area 1–3 cm from the capsule.